NS5B binds ribavirin

Stable Identifier
R-HSA-9680836
Type
Reaction [omitted]
Species
Homo sapiens
Related Species
Hepatitis C Virus
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA, possessing a broad-spectrum activity against several RNA and DNA viruses. It is primarily indicated for use in treating hepatitis C (HCV) and viral hemorrhagic fevers. Ribavirin is reported to have several mechanisms of actions that lead to inhibition of viral RNA and protein synthesis. After activation by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites, ribavirin triphosphate (RTP) is the predominant metabolite which directly inhibits viral mRNA polymerase by binding to the nucleotide binding site of the enzyme. Here, ribavirin binding to NS5B, the viral mRNA polymerase of HCV is annotated. This binding prevents the binding of the correct nucleotides, leading to a reduction in viral replication or to the production of defective virions (Te et al. 2007).

Ribavirin is currently being investigated for patients with COVID-19 (Chinese clinical trial registry no. ChiCTR2000029387) (Elfiky 2020).

Literature References
PubMed ID Title Journal Year
32119961 Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Elfiky, AA

Life Sci. 2020
21960835 Mechanism of action of ribavirin in the treatment of chronic hepatitis C

Te, HS, Randall, G, Jensen, DM

Gastroenterol Hepatol (N Y) 2007
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!